Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:227-30.
doi: 10.2147/opth.s5053. Epub 2009 Jun 2.

Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma

Dimitris Papaconstantinou  1 , Ilias Georgalas, Nikolaos Kourtis, Christos Pitsas, Efthimios Karmiris, Chrysanthi Koutsandrea, Ioannis Ladas, Gerasimos Georgopoulos
Affiliations

Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma

Dimitris Papaconstantinou et al. Clin Ophthalmol. 2009.

Abstract

Purpose: The purpose of this prospective study was to evaluate the efficacy in intraocular pressure (IOP) control and the tolerance of a topically administered fixed combination of timolol-brimonidine in 50 patients with ocular hypertension and primary open-angle glaucoma.

Methods: After determining a baseline IOP, the fixed combination timolol-brimonidine was used twice daily for two months, while IOP, ophthalmic signs, and/or symptoms were monitored.

Results: The mean IOP value was decreased from 23.09 mm Hg (+/-1.98 SD) to 17.46 mm Hg (+/-1.47 SD) during the 1st month (paired Student's t test = 9.88 kappaalphaiota p < 0.001), and to 17.51 mm Hg (+/-1.43 SD) in the 2nd month. Between the 1st and 2nd month, no statistical difference was observed (paired Student's t test = 0.02 kappaalphaiota p > 0.1). In 8% of the patients during the 1st month and 10% of patients in the 2nd month, some ophthalmic signs were observed, while only mild ophthalmic symptoms were reported in 6% and 8% of the patients, respectively.

Conclusions: In conclusion, the fixed combination of timolol-brimonidine has a satisfactory IOP-lowering effect without any serious side effects due to the topical use.

Keywords: fixed combination 0.2% brimonidine–0.5% timolol; ocular hypertension; primary open-angle glaucoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean intraocular pressure (IOP) change.
See this image and copyright information in PMC

References

    1. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Advanced Glaucoma Intervention Study Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627–1635. - PubMed
    1. Bengtsson B, Leske MC, Hyman L, Heijl A, Early Manifest Glaucoma Trial Group Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:205–209. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279. - PubMed
    1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720. - PubMed
    1. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230–1238. - PubMed

LinkOut - more resources